logo

Cyclo Therapeutics, Inc. (CYTH)



Trade CYTH now with
  Date
  Headline
10/4/2022 8:09:13 AM Cyclo Commences Phase 2b Study Of Trappsol Cyclo For Treatment Of Early Alzheimer's Disease
8/16/2022 8:22:55 AM Cyclo Therapeutics Q2 Net Loss/shr $0.41 Vs. Loss/shr $0.56 Last Year
3/24/2022 8:14:07 AM Cyclo Enters Into Agreement With Wits Commercial Enterprise To Explore Potential Applications Of Trappsol Cyclo
12/6/2021 8:10:41 AM Cyclo Receives IND Clearance From FDA To Advance Phase 2 Study Of Trappsol Cyclo For Treatment Of Alzheimer's Disease
11/16/2021 8:36:22 PM Cyclo Therapeutics Prices Public Offering Of 1.95 Mln Shares At $6.00/shr
10/18/2021 8:09:56 AM Cyclo Therapeutics Announces Abstract Accepted For Poster Presentation
8/17/2021 8:16:30 AM Cyclo Therapeutics Q2 Net Loss $3.6 Mln Or $0.56/shr Vs. Loss $2.19 Mln Or $1.61/shr Prior Year
6/17/2021 8:13:04 AM Cyclo Therapeutics Commences Patient Enrollment In Phase 3 Study Of Trappsol Cyclo In Niemann-Pick Type C1
5/11/2021 9:07:55 AM Cyclo Therapeutics Names Lori McKenna Gorski Global Head Of Patient Advocacy
4/20/2021 9:28:31 AM Cyclo Gets FDA Feedback Supporting Development Strategy To Submit IND Application For Phase 2 Study Of Trappsol Cyclo
3/25/2021 8:39:24 AM Cyclo Therapeutics Meets Primary Efficacy Endpoint In Phase 1/2 Trial From Intravenous Trappsol Cyclo
3/10/2021 8:36:38 AM Cyclo Therapeutics Names Russ Belden Acting Chief Commercial Officer
3/9/2021 9:09:39 AM Cyclo Gets Positive Opinion From Paediatric Committee Of EMA On Agreement Of PIP For Trappsol Cyclo
3/4/2021 9:14:07 AM Cyclo Therapeutics Says Last Patient Completed Their Last Visit In The Phase 1/2 Study Evaluating Trappsol